Transgene Biotek is currently trading at Rs. 10.30, up by 0.04 points or 0.39% from its previous closing of Rs. 10.26 on the BSE.
The scrip opened at Rs. 10.40 and has touched a high and low of Rs. 10.50 and Rs. 9.81 respectively. So far 410123 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 62.50 on 16-Nov-2011 and a 52 week low of Rs. 8.95 on 13-Aug-2012.
Last one week high and low of the scrip stood at Rs. 11.39 and Rs. 9.81 respectively. The current market cap of the company is Rs. 67.35 crore.
The promoters holding in the company stood at 9.78% while Institutions and Non-Institutions held 1.86% and 14.92% respectively.
Transgene Biotek is geared up to launch one of its block-buster drugs - TrabiDHA (DHA) formulations. With the successful development of TrabiDHA in both oil and powder forms, the company is now actively pursuing several formulations in the form of soft and hard capsules and into several other formulations to cater to the hugely expanding neutraceutical markets containing DHA, apart from catering to the demands from animal health care division too.
Transgene Biotek is the first Indian company to undertake the entire spectrum of vegetable DHA range from the production to the final formulations. DHA is essential for the proper functioning of brains as adults, and for the development of nervous system and visual abilities during the first 6 months of life. In addition, omega-3 fatty acids are part of a healthy diet that helps lower risk of heart disease.
Transgene Biotek, is a biotechnology company. It is involved in the development of several cutting edge technologies.
Company Name | CMP |
---|---|
Apollo Hospital Ent. | 7036.65 |
Max Healthcare Inst | 1006.75 |
Narayana Hrudayalay | 1249.35 |
Aster DM Healthcare | 444.55 |
Global Health | 1115.50 |
View more.. |